Analyst firms · H.C. Wainwright · AKBA
H.C. Wainwright AKBA price target and rating history
Akebia Therapeutics Inc. (AKBA) · Health Care
H.C. Wainwright rates Akebia Therapeutics Inc. (AKBA) Buy with a $8 price target, as of its latest action on Jun 4, 2025. It has published 4 rating actions on AKBA since November 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $8
- Median target, all firms
- Too few
- Actions on AKBA
- 4
H.C. Wainwright price target on AKBA
Every H.C. Wainwright rating on AKBA
- Jun 4, 2025
- Aug 28, 2023
- Mar 31, 2022
- Nov 11, 2021
Questions about H.C. Wainwright and AKBA
- What is H.C. Wainwright's price target for AKBA?
- H.C. Wainwright's latest stated price target for Akebia Therapeutics Inc. (AKBA) is $8, from its action on Jun 4, 2025.
- What is H.C. Wainwright's rating on AKBA?
- H.C. Wainwright rates AKBA Buy, a bullish rating, as of Jun 4, 2025.
- When did H.C. Wainwright last change its view on AKBA?
- On Jun 4, 2025, H.C. Wainwright resumes coverage at Buy, price target $8.
All H.C. Wainwright ratingsAKBA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.